← Back to Screener
Day One Biopharmaceuticals, Inc. Common Stock (DAWN)
Price$21.48
Favorite Metrics
Price vs S&P 500 (26W)187.80%
Price vs S&P 500 (4W)-9.35%
Market Capitalization$2.22B
All Metrics
Book Value / Share (Quarterly)$4.28
P/TBV (Annual)2.26x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.04
Price vs S&P 500 (YTD)126.23%
Gross Margin (TTM)89.12%
Net Profit Margin (TTM)-67.85%
EPS (TTM)$-1.04
10-Day Avg Trading Volume1.35M
EPS Excl Extra (TTM)$-1.04
EPS (Annual)$-1.04
ROI (Annual)-24.33%
Gross Margin (Annual)89.12%
Cash / Share (Quarterly)$4.28
Revenue Growth QoQ (YoY)83.92%
ROA (Last FY)-21.13%
EBITD / Share (TTM)$-1.23
ROE (5Y Avg)-40.27%
Operating Margin (TTM)-80.76%
Cash Flow / Share (Annual)$-1.04
P/B Ratio5.03x
P/B Ratio (Quarterly)2.17x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)12.77x
Net Interest Coverage (TTM)-0.46x
ROA (TTM)-20.69%
EPS Incl Extra (Annual)$-1.04
Current Ratio (Annual)8.02x
Quick Ratio (Quarterly)7.73x
3-Month Avg Trading Volume3.73M
52-Week Price Return217.60%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$4.11
P/S Ratio (Annual)14.02x
Asset Turnover (Annual)0.31x
52-Week High$21.49
EPS Excl Extra (Annual)$-1.04
CapEx CAGR (5Y)111.62%
26-Week Price Return196.55%
Quick Ratio (Annual)7.73x
13-Week Price Return100.09%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.02x
Enterprise Value$2,020.723
Asset Turnover (TTM)0.30x
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-69.10%
Cash / Share (Annual)$4.28
3-Month Return Std Dev150.86%
Net Income / Employee (TTM)$-1
ROE (Last FY)-24.33%
Net Interest Coverage (Annual)-1.93x
EPS Basic Excl Extra (Annual)$-1.04
Receivables Turnover (TTM)7.79x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.04
ROI (TTM)-23.43%
P/S Ratio (TTM)14.02x
Revenue / Share (Annual)$1.53
Tangible BV / Share (Annual)$4.11
Price vs S&P 500 (52W)182.51%
Year-to-Date Return130.36%
5-Day Price Return-0.09%
EPS Normalized (Annual)$-1.04
ROA (5Y Avg)-37.47%
Net Profit Margin (Annual)-67.85%
Month-to-Date Return0.14%
Cash Flow / Share (TTM)$-2.29
EBITD / Share (Annual)$-1.23
Operating Margin (Annual)-80.76%
ROI (5Y Avg)-40.27%
EPS Basic Excl Extra (TTM)$-1.04
P/TBV (Quarterly)2.26x
P/B Ratio (Annual)2.17x
Inventory Turnover (TTM)3.57x
Pretax Margin (TTM)-69.10%
Book Value / Share (Annual)$4.28
Price vs S&P 500 (13W)97.23%
Beta-1.70x
Revenue / Share (TTM)$1.53
ROE (TTM)-23.43%
52-Week Low$5.63
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
2.62
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
DAWNDay One Biopharmaceuticals, Inc. Common Stock | 14.02x | — | 89.12% | — | $21.48 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for genetically defined cancers, with initial focus on pediatric oncology, an underserved market with significant unmet medical needs. The company's lead candidate, DAY301, is an antibody-drug conjugate (ADC) that has demonstrated antitumor activity in preclinical studies.